Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to study if patients that undergo catheter ablation for ventricular tachycardia benefit from continuation of Vaughan-Williams class III antiarrhythmic drugs for 3 months after their ablation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Treatments: Amiodarone; Anti-Arrhythmia Agents; Sotalol

Criteria

Inclusion Criteria:

1. Age >18 years.

2. Able to give written, informed consent

3. Structural heart disease.

4. Implanted and normally functioning ICD or undergoing ICD implant at index admission.

5. Undergoing initial radiofrequency ablation procedure for sustained monomorphic VT.

6. Receiving a class III AADs prior to VT ablation.

7. No VT inducible at the end of VT ablation.

8. No VT inducible on non-invasive programmed stimulation following VT ablation.

Exclusion Criteria:

1. LV assist device in place

2. Decompensated heart failure and/or requiring continuous inotropic therapy and/or awaiting cardiac transplantation

3. Ongoing acute coronary syndrome.

4. Mechanical prosthetic aortic and mitral valves.

5. Pedunculated or mobile left ventricular thrombus.

6. Persistent VT at the end of index catheter ablation.

7. Absolute contraindications for class III AADs.

8. Participation in other trial.

9. VT induced on NIPS after VT ablation.

10. Another reason for continuation of class III AADs (i.e., atrial fibrillation).